tambotatug pelitecan + toripalimab + cisplatin

YL201 + toripalimab + cisplatin is an investigational combination regimen consisting of the B7-H3-targeted antibody-drug conjugate (ADC) tambotatug pelitecan (YL201), the anti-PD-1 monoclonal antibody toripalimab, and the platinum-based chemotherapeutic agent cisplatin. Tambotatug pelitecan (YL201) is developed by MediLink Therapeutics and licensed to Roche; it consists of a human anti-B7-H3 monoclonal antibody conjugated to a camptothecin-type topoisomerase I inhibitor payload via a tumor-microenvironment-activable linker. Toripalimab is a PD-1-blocking monoclonal antibody developed by Junshi Biosciences. Cisplatin is a standard DNA-damaging cytotoxic chemotherapy. This triplet combination is being evaluated in a Phase 1/2 clinical trial (NCT07258979) for the treatment of recurrent or metastatic nasopharyngeal carcinoma.